Syneos Health and Elligo Announce Strategic Collaboration to Advance Clinical Research for Real-World Patients
AUSTIN, Texas and RALEIGH, N.C.,
|
Applying its Goes Direct® approach, Elligo identifies patients for clinical trials using electronic health records and then provides their physicians with the infrastructure to conduct the research in their own practices. This platform enables research at practices that historically would not have had the infrastructure to conduct clinical research.
The collaboration will seek to build a centrally managed infrastructure and regulatory research system around physicians and patients who have not typically been accessible in traditional sites. This could include deploying expert staff and providing the training and regulatory guidance needed to run a trial, removing physician burden and focusing the experience around the patient.
The ability to bring clinical research to underrepresented populations through community medical practices, evolving from a location-bound approach, to a centrally managed systemic approach, redefines the clinical trial site footprint. This effort should improve quality, reduce timelines and save costs.
“Our biopharma acceleration model is designed to completely surround the patient, caregiver or any stakeholder with the most relevant solutions to make the clinical trial process easier and more accessible. Our collaboration with Elligo allows us to do just that,” said Alistair Macdonald, chief executive officer,
“We are thrilled to collaborate with
To learn more about how
About
About Elligo
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct® approach uses state-of-the-art technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.
Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: risks associated with the integration of the Company's business with the business of inVentiv Health and its operation of the combined business following the closing of the Merger; the Company's ability to maintain or generate new business awards; the Company's ability to increase its market share, grow its business, and execute its growth strategies; the Company's backlog not being indicative of future revenues and its ability to realize the anticipated future revenue reflected in its backlog; the impact of adoption of the new accounting standard of recognizing revenue from customers; the impact of the Tax Act; the Company's ability to adequately price its contracts and not overrun cost estimates; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; fluctuations in the Company's financial results; reliance on key personnel; customer or therapeutic area concentration; and the other risk factors set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and other SEC filings, copies of which are available free of charge on the Company's website at investor.syneoshealth.com. Syneos Health assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Lea Studer
Elligo Health Research
+1 402 366 1752
lea@scorrmarketing.com
Danielle DeForge
Syneos Health
+1 202 210 5992
danielle.deforge@syneoshealth.com
Source: Syneos Health